Cell Signaling Technology

Product Pathways - DNA Damage

Doxorubicin #5927

Molecular Formula:
C27H29NO11 • HCl
Molecular Weight:
579.98 g/mol
Purity:
>99%

Directions for Use

Doxorubicin is supplied as a lyophilized powder. For a 10 mM stock, reconstitute the 5 mg in 860 µl DMSO. Working concentrations and length of treatments vary depending on the desired effect, but it is typically used at 0.1-5 µM for 12-24 hours. Soluble in DMSO at 100 mg/ml; very poorly soluble in ethanol; soluble in water at 10 mg/ml with slight warming.

Western Blotting

Western Blotting

Western blot analysis of extracts from HeLa cells, untreated, treated with Doxorubicin (0.5 µM, 24 hr), or treated with Trichostatin A (TSA) #9950 (400 nM, 24 hr) and Doxorubicin (0.5 µM, 24 hr), using Acetyl-p53 (Lys382) Antibody #2525 (upper) or p53 (1C12) Mouse mAb #2524 (lower).

Western Blotting

Western Blotting

Western blot analysis of extracts from HeLa cells, serum-starved overnight and untreated or treated with Doxorubicin (5 μM) for the indicated times, using Phospho-p53 (Ser15) Antibody #9284, p53 Antibody #9282, Cleaved Caspase-3 (Asp175) Antibody #9661, or PARP Antibody #9542.

Structure

Structure

Chemical structure of doxorubicin.


Background

Doxorubicin, an anthracycline antibiotic, inhibits DNA and RNA synthesis in mammalian cells and has been shown to be a very effective anti-tumor agent (1,2). Doxorubicin binds to nucleic acids by intercalating the DNA double helix and stabilizing topoisomerase II cleavage complexes, leading to DNA strand breaks at specific doxorubicin-induced sites (3). Doxorubin has been shown to inhibit DNA synthesis in a dose-dependent manner in MCF7 cells, which corresponds closely with growth inhibition (4). Researchers have also demonstrated that doxorubicin effectively inhibits human DNA topoisomerase I (5).

  1. Kim, S.H. and Kim, J.H. (1972) Cancer Res 32, 323-5.
  2. Momparler, R.L. et al. (1976) Cancer Res 36, 2891-5.
  3. Capranico, G. et al. (1990) Nucleic Acids Res 18, 6611-9.
  4. Fornari, F.A. et al. (1994) Mol Pharmacol 45, 649-56.
  5. Foglesong, P.D. et al. (1992) Cancer Chemother Pharmacol 30, 123-5.

Application References

Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!

For Research Use Only. Not For Use In Diagnostic Procedures.

Products